We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

SEC Filings

Form 424B5
AC IMMUNE SA filed this Form 424B5 on 07/17/2018
Document Outline
Entire Document (840.4 KB)
Subdocument 1 - 424B5 - FORM 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - Joint Book-Running Managers
Page 3 - TABLE OF CONTENTS
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - AC Immune SA
Page 9 - Our Strategy
Page 10 - N/A
Page 11 - Corporate Information
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - Risks Related to Our Common Shares, the Public Offering and the First Rights Offering
Page 18 - Shareholders may not be able to exercise pre-emptive subscription rights.
Page 19 - There is only a limited free float of our common shares; this may have a negative impact on the liqu
Page 20 - We have broad discretion in the use of our cash and cash equivalents and may not use them effectivel
Page 21 - Our status as a Swiss corporation may limit our flexibility with respect to certain aspects of capit
Page 22 - U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our
Page 23 - Swiss law restricts our ability to pay dividends.
Page 24 - We may lose our foreign private issuer status, which would then require us to comply with the Exchan
Page 25 - As a result of being a public company we incur additional costs and we may not manage to comply with
Page 26 - Although we believe that we were not a passive foreign investment company, or PFIC, for U.S. federal
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - The First Rights Offering
Page 32 - The Offered Shares
Page 33 - The Second Rights Offering
Page 34 - N/A
Page 35 - Swiss Tax considerations
Page 36 - Taxation in respect of Offered Shares
Page 37 - Swiss income taxes
Page 38 - International Automatic Exchange of Information
Page 39 - Taxation of Distributions
Page 40 - Sale or Other Disposition of Common Shares
Page 41 - Information Reporting and Backup Withholding
Page 42 - Commission and Expenses
Page 43 - Option to Purchase Additional Shares
Page 44 - N/A
Page 45 - N/A
Page 46 - Stabilization
Page 47 - Disclaimers About Non-U.S. Jurisdictions
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - N/A
Page 53 - TABLE OF CONTENTS
Page 54 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 55 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 56 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 57 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 58 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 59 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 60 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 61 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 62 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 63 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 64 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 65 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 66 - Investing in our securities involves risks. See Risk Factors beginning on page 4 of this prospectus.
Page 67 - N/A
Page 68 - Neither the delivery of this prospectus nor any sale made under it implies that there has been no ch
Page 69 - N/A
Page 70 - N/A
Page 71 - N/A
Page 72 - N/A
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - Common Shares